We are live on ! Find out more
ATNM icon

Actinium Pharmaceuticals
ATNM

26 hedge funds and large institutions have $5.14M invested in Actinium Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,286% more call options, than puts

Call options by funds: $97K | Put options by funds: $7K

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

0.02% more ownership

Funds ownership: 0.22% → 0.24% (+0.02%)

4% less funds holding

Funds holding: 27 → 26 (-1)

9% less capital invested

Capital invested by funds: $5.65M → $5.14M (-$510K)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
26
Holders Change
-1
Holders Change %
-3.7%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
4
Closed
4
Calls
$97K
Puts
$7K
Net Calls
+$90K
Net Calls Change
+$50K

Top Buyers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
+$559K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$207K
3
BCM
Bridgeway Capital Management
Texas
+$114K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$55.7K
5
ARTA
A.R.T. Advisors
New York
+$21.1K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$136K
2
Renaissance Technologies
Renaissance Technologies
New York
-$114K
3
RJA
Raymond James & Associates
Florida
-$23K
4
TSS
Two Sigma Securities
New York
-$20K
5
UBS Group
UBS Group
Switzerland
-$20K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.62M +$207K +4,952 +7%
BlackRock
2
BlackRock
New York
$737K -$136K -3,255 -14%
VKH
3
Virtu KCG Holdings
New York
$540K +$559K +13,369 +958%
BCM
4
Bridgeway Capital Management
Texas
$393K +$114K +2,736 +34%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$233K +$55.7K +1,332 +26%
DADC
6
D.A. Davidson & Co
Montana
$156K – – –
Northern Trust
7
Northern Trust
Illinois
$130K – – –
Bank of New York Mellon
8
Bank of New York Mellon
New York
$59K – – –
California Public Employees Retirement System
9
California Public Employees Retirement System
California
$49K – – –
Morgan Stanley
10
Morgan Stanley
New York
$32K -$126 -3 -0.3%
DY
11
Dowling & Yahnke
California
$28K – – –
Group One Trading
12
Group One Trading
Illinois
$22K – – –
RJFSA
13
Raymond James Financial Services Advisors
Florida
$22K – – –
Barclays
14
Barclays
United Kingdom
$18K – – –
ARTA
15
A.R.T. Advisors
New York
$18K +$21.1K +504 New
SFG
16
SNS Financial Group
Minnesota
$15K +$2.8K +67 +20%
Renaissance Technologies
17
Renaissance Technologies
New York
$14K -$114K -2,729 -88%
State Street
18
State Street
Massachusetts
$14K – – –
SXL
19
Summit X LLC
Missouri
$13K +$15.4K +367 New
HFM
20
Hartford Financial Management
Connecticut
$8K – – –
AG
21
Advisor Group
Arizona
$5K – – –
Royal Bank of Canada
22
Royal Bank of Canada
Ontario, Canada
$5K – – –
Creative Planning
23
Creative Planning
Kansas
$5K +$2.09K +50 +62%
Bank of Montreal
24
Bank of Montreal
Ontario, Canada
$3K – – –
AIM
25
Acrospire Investment Management
Illinois
$2K -$5.44K -130 -67%
1
2

ATNM Hedge Fund Activity: Q2 2017 in Review

26 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q2 2017, worth a combined $5.14M — down 9% from $5.65M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ATNM and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.

The largest buyer was Virtu KCG Holdings, adding an estimated $559K. The largest seller was BlackRock, cutting an estimated $136K.

  • 26 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q2 2017, down from 27 in Q1 2017.
  • Funds reported $5.14M of Actinium Pharmaceuticals stock for Q2 2017, down 9% quarter-over-quarter.
  • 3 funds opened new Actinium Pharmaceuticals positions in Q2 2017 and 4 closed out, a net change of -1 holder.
  • The largest Actinium Pharmaceuticals buyer in Q2 2017 was Virtu KCG Holdings, an estimated $559K added.
  • The largest Actinium Pharmaceuticals seller in Q2 2017 was BlackRock, an estimated $136K sold.

Based on aggregated 13F filings for Q2 2017.